Media Center

 

Third Rock News & Events

January 26, 2017 - Third Rock Ventures Names Sarah Larson as Partner
» Read More

October 31, 2016 - Third Rock Ventures Raises $616 Million Fund IV
» Read More

September 24, 2016 - Third Rock Ventures’ Venture Partner Phil Reilly to receive the Henri Termeer Lifetime Achievement Award at the 5th Annual Tribute to Champions of Hope
» Read More

May 23, 2016 - Third Rock Ventures’ Venture Partner Phil Reilly to Speak at MassBio Event to Discuss his New Book “Orphan: The Quest to Save Children with Rare Disease”
» Read More

April 25, 2016 - Third Rock Ventures' Partner, Robert Tepper, to Moderate Panel at the World Medical Innovation Forum
» Read More

April 6, 2016 - Third Rock Ventures' Partner, Cary Pfeffer, to Present at Xconomy's EXOME: What's Hot in Boston Biotech
» Read More

Portfolio News

REVOLUTION Medicines
October 16, 2018 - REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
» Press Release | Company News

Kala Pharmaceuticals
October 11, 2018 - Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
» Press Release | Company News

Constellation Pharmaceuticals
October 10, 2018 - Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
» Press Release | Company News

Nurix, Inc.
October 10, 2018 - Nurix Therapeutics to Present at the 2018 BIO Investor Forum
» Press Release | Company News

Rheos Medicines
October 10, 2018 - Rheos Medicines Expands Leadership Team with Appointments of Gad Soffer as Chief Operating Officer and J. Duncan Higgons to Board of Directors
» Press Release | Company News

Tango Therapeutics
October 10, 2018 - Tango Therapeutics Appoints Malte Peters, MD, to Board of Directors
» Press Release | Company News

Relay Therapeutics
October 9, 2018 - Relay Therapeutics Names Linda A. Hill, Ph.D., to Its Board of Directors
» Press Release | Company News

REVOLUTION Medicines
October 9, 2018 - REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
» Press Release | Company News

CytomX Therapeutics
October 8, 2018 - CytomX Therapeutics Announces Presentations at 2018 ESMO Annual Meeting
» Press Release | Company News

Blueprint Medicines
October 6, 2018 - Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers
» Press Release | Company News

News Archives